Neurofibroma surgery: Difference between revisions

Jump to navigation Jump to search
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Neurofibroma}}
{{Neurofibroma}}
{{CMG}}; {{AE}} {{SC}}
{{CMG}}; {{AE}}{{S.M.}} {{SC}}
==Overview==
==Overview==
[[Surgery]] is the mainstay of treatment for [[neurofibroma]]. Localized and [[diffuse]] [[lesions]] are usually treated [[Surgery|surgically]]. [[Neurofibroma|Neurofibromas]] that [[Infiltration (medical)|infiltrate]] between [[nerve]] [[fascicles]] are unable to be separated from the parent [[nerve]], therefore, deep-seated [[lesions]] are often [[Managed Care|managed]] conservatively. Local [[Recurrence plot|recurrence]] after [[excision]] is uncommon .and [[malignant transformation]] occurs [[Rare|rarely]].


==Surgery==
==Surgery==
'''Localised neurofibroma/Diffuse neurofibroma'''
'''Localised neurofibroma and Diffuse neurofibroma (not associated with NF-1)'''
* Localised and diffuse lesions may be treated surgically.
* Localized and [[diffuse]] [[lesions]] are usually treated [[Surgery|surgically]]<ref name="radio">Neurofibroma. Dr Bruno Di Muzio and Dr Maxime St-Amant et al. Radiopaedia.org 2015. http://radiopaedia.org/articles/neurofibroma Accessed on November 17, 2015 </ref>
* Neurofibromas that infiltrate between nerve fascicles are unable to be separated from the parent nerve, therefore, deep-seated lesions are often managed conservatively.
* [[Neurofibroma|Neurofibromas]] that [[Infiltration (medical)|infiltrate]] between [[nerve]] [[fascicles]] are unable to be separated from the parent [[nerve]], therefore, deep-seated [[lesions]] are often [[Managed Care|managed]] conservatively
* Local recurrence after excision is uncommon and malignant transformation is rare.
* Local [[Recurrence plot|recurrence]] after [[excision]] is uncommon
*  [[malignant transformation]] occurs [[Rare|rarely]]


'''Plexiform neurofibroma'''
'''Plexiform neurofibroma (NF-1 associated)'''
* The primary treatment option for [[plexiform neurofibroma]] is [[surgery]].<ref>{{cite journal  |vauthors=Packer RJ, Gutmann DH, Rubenstein A, etal |title=Plexiform neurofibromas in NF1: toward biologic-based therapy |journal=Neurology |volume=58 |issue=10 |pages=1461–70 |date=May 2002  |pmid=12041525 |url=http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12041525 |doi=10.1212/wnl.58.10.1461}}</ref>
* The primary treatment option for [[plexiform neurofibroma]] is not [[surgery|surgery,]] until and unless:
* Removal of plexiform neurofibromas is difficult because they can be large and cross tissue boundaries. 
**Debilitating [[symptoms]] are present
* Plexiform neurofibroma is found in approximately 30% of patients with [[neurofibromatosis type 1]] (NF1).
**There is a [[Possibility theory|possibility]] of [[malignant transformation]]<ref>{{cite journal  |vauthors=Packer RJ, Gutmann DH, Rubenstein A, etal |title=Plexiform neurofibromas in NF1: toward biologic-based therapy |journal=Neurology |volume=58 |issue=10 |pages=1461–70 |date=May 2002  |pmid=12041525 |url=http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12041525 |doi=10.1212/wnl.58.10.1461}}</ref><ref name="radio" />
* due to multiplicity of lesions, unless debilitating symptoms are present, treatment of patients with NF1 is often non-surgical.
* Removal of [[plexiform neurofibroma]]s is difficult because they can be large and cross [[tissue]] boundaries hence, leading to incomplete [[resection]]
* Plexiform neurofibromas are particularly difficult to resect, often leading to incomplete resection.
* [[Recurrence plot|Recurrence]] after [[resection]] is frequent
* Recurrence after resection is frequent


==References==
==References==
Line 27: Line 28:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Latest revision as of 01:31, 29 April 2019

Neurofibroma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neurofibroma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neurofibroma surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurofibroma surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurofibroma surgery

CDC on Neurofibroma surgery

Neurofibroma surgery in the news

Blogs on Neurofibroma surgery

Directions to Hospitals Treating Neurofibroma

Risk calculators and risk factors for Neurofibroma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]

Overview

Surgery is the mainstay of treatment for neurofibroma. Localized and diffuse lesions are usually treated surgically. Neurofibromas that infiltrate between nerve fascicles are unable to be separated from the parent nerve, therefore, deep-seated lesions are often managed conservatively. Local recurrence after excision is uncommon .and malignant transformation occurs rarely.

Surgery

Localised neurofibroma and Diffuse neurofibroma (not associated with NF-1)

Plexiform neurofibroma (NF-1 associated)

References

  1. 1.0 1.1 Neurofibroma. Dr Bruno Di Muzio and Dr Maxime St-Amant et al. Radiopaedia.org 2015. http://radiopaedia.org/articles/neurofibroma Accessed on November 17, 2015
  2. Packer RJ, Gutmann DH, Rubenstein A, et al. (May 2002). "Plexiform neurofibromas in NF1: toward biologic-based therapy". Neurology. 58 (10): 1461–70. doi:10.1212/wnl.58.10.1461. PMID 12041525.


Template:WikiDoc Sources